Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Income (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Net Income for 9 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 31.92% year-over-year to $17.0 million, compared with a TTM value of $35.2 million through Dec 2025, up 50.01%, and an annual FY2024 reading of $24.1 million, up 2325.3% over the prior year.
  • Net Income was $17.0 million for Q4 2025 at Puma Biotechnology, up from $9.1 million in the prior quarter.
  • Across five years, Net Income topped out at $20.0 million in Q3 2024 and bottomed at -$44.7 million in Q3 2021.
  • Average Net Income over 5 years is $2.1 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Net Income skyrocketed 1531.11% in 2023, then plummeted 443.68% in 2024.
  • Year by year, Net Income stood at $4.1 million in 2021, then skyrocketed by 75.99% to $7.3 million in 2022, then tumbled by 243.41% to -$10.4 million in 2023, then surged by 223.57% to $12.9 million in 2024, then skyrocketed by 31.92% to $17.0 million in 2025.
  • Business Quant data shows Net Income for PBYI at $17.0 million in Q4 2025, $9.1 million in Q3 2025, and $6.2 million in Q2 2025.